Bayer reaches settlement with Cipla over trademark infringement claims

Shawnee, Kan.

— Bayer HealthCare reached settlements in its trademark infringement claims against India-based Cipla Ltd. and Vanuatu-based Archipelago Suppliers, an operator of several websites. According to the settlement, both companies have agreed to immediately stop selling products that infringe on

Bayer's Advantage® and Advantix® trademarks. The companies also agreed to disgorge profits from such sales.

Bayer sought a preliminary injunction to block Cipla's manufacture of DA Double Advantage and sales by various websites to U.S. consumers. Bayer contends Cipla was in violation of Bayer's Advantage® trademark rights.

As a result of the settlement, Cipla agreed to discontinue all use of the DA Double Advantage trademark (in the United States and globally). Cipla will also stop use of the trademark Advance for a companion-animal product; refrain from manufacturing any product with the same formula as Bayer's patented Advantix® (Global) and K9 Advantix® II (U.S.) products during the remaining term of those patents, the company reports in a prepared statement.